U.S. Markets close in 2 hrs 21 mins

Akers Biosciences, Inc. (AKER)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
5.31+0.02 (+0.38%)
As of 1:38PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.29
Open5.44
Bid5.30 x 1000
Ask5.31 x 1200
Day's Range5.23 - 5.44
52 Week Range1.55 - 16.32
Volume192,054
Avg. Volume1,211,870
Market Cap32.524M
Beta (5Y Monthly)0.40
PE Ratio (TTM)N/A
EPS (TTM)-6.29
Earnings DateAug 13, 2020 - Aug 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Akers Biosciences and Premas Biotech Announce Initiation of Animal Studies

    Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, the initiation of animal studies for its SARS-CoV-2 vaccine candidate in India. Premas has successfully completed the manufacturing process for the VLP (virus like particle) vaccine candidate, including three antigens from SARS-CoV-2. Premas plans to administer the test across different dose amounts, including amounts that would be applicable to humans.

  • Hedge Funds Are Nibbling On Akers Biosciences Inc (AKER)
    Insider Monkey

    Hedge Funds Are Nibbling On Akers Biosciences Inc (AKER)

    At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

  • GlobeNewswire

    Akers Biosciences Closes $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced the closing of its previously announced registered direct offering of an aggregate of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share priced at-the-market under Nasdaq rules. The gross proceeds to the Company from this offering was approximately $4.8 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The shares of common stock were offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-234449) previously filed with the Securities and Exchange Commission (the "SEC") on November 1, 2019, and declared effective by the SEC on April 7, 2020.